IP Library › Granted Patent US 12,390,448
Granted Patent B2
US 12,390,448 · App. 18/178,941 · Granted Aug 19, 2025

Prevention or of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans

Inventor: Maria Maccecchini (West Chester, PA)
Assignee: ANNOVIS BIO, INC.
A61K31/407A61K9/0053A61P3/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,390,448
App. No.
18/178,941
Granted
Aug 19, 2025
Kind
B2
Abstract

The invention relates in part to a method of maintaining heavy metal homeostasis in healthy humans, comprising chronically administering to healthy humans a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis. By virtue of this method, prophylactic treatment of a potential disease state such as a neurodegenerative disease, cardiovascular homeostasis, cancer, vital organ homeostasis, and the like. The invention also relates in part to a method of restoring heavy metal homeostasis in sick patients, comprising chronically administering to a sick patient a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of Posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis. By virtue of this method, treatment of a potential disease state such as a neurodegenerative disease, cardiovascular disease, cancer, vital organ dysfunction and heavy metal dis-homeostasis, and the like.

Claims (20)

1. A method of maintaining heavy metal homeostasis in a healthy human or restoring heavy metal homeostasis in a sick human patient, comprising chronically administering a pharmaceutical composition comprising an active agent selected from the group consisting of Posiphen and pharmaceutically acceptable salts thereof, together with one or more pharmaceutically acceptable excipients in a therapeutically effective amount to maintain heavy metal homeostasis in the healthy human patient or restore heavy metal homeostasis in the sick human patient.

2. The method of claim 1 , wherein the metal is iron.

3. The method of claim 1 , wherein Posiphen is administered in an amount from about 1 mg to less than about 200 mg.

4. The method of claim 3 , wherein Posiphen is administered orally on a once-a-day basis.

5. The method of claim 1 , wherein Posiphen is administered in an amount from about 1 mg to about 30 mg, per day.

6. The method of claim 5 , wherein Posiphen is administered orally.

7. The method of claim 1 , wherein the chronic administration maintains heavy metal homeostasis in the healthy human.

8. The method of claim 1 , wherein the chronic administration restores heavy metal homeostasis in the sick human patient.

9. The method of claim 1 , wherein the administration of Posiphen prevents, stops, slows or delays the onset of a neurodegenerative disease or condition in a healthy human.

10. The method of claim 1 , wherein the administration of Posiphen is to a sick human patient suffering from a neurodegenerative disease.

11. The method of claim 10 , wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Down Syndrome, alpha-synucleopathies, Parkinson's disease, Huntington's disease, Prion's disease, Amyloid Lateral Sclerosis, Multiple Sclerosis, Tauopathies and other chronic and acute neurodegenerative disorders.

12. The method of claim 1 , wherein the administration of Posiphen prevents, stops, slows or delays the onset of cancer in the healthy human.

13. The method of claim 1 , wherein the administration of Posiphen prevents, stops, slows or delays the course of cancer in a sick human patient suffering from cancer.

14. The method of claim 1 , wherein the administration of Posiphen prevents, stops, slows or delays the onset of cardiovascular disease in the healthy human.

15. The method of claim 1 , wherein the administration of Posiphen prevents, stops, slows or delays the course of cardiovascular disease in the sick human patient.

16. The method of claim 1 , wherein the administration of Posiphen maintains homeostasis in vital organs in the healthy human.

17. The method of any of claim 1 , wherein the administration Posiphen restores homeostasis in vital organs in the sick human patient.

18. The method of claim 17 , wherein the vital organ is selected from brain, heart, lung, liver, a kidney.

19. The method of claim 1 , wherein the chronic administration is to a patient who has suffered an acute injury/incidence such that there is stasis or amelioration of symptoms or effects of the acute injury/incidence.

20. The method of claim 1 , wherein Posiphen is administered via a route selected from the group consisting of oral, parenteral, sublingual, a suppository, nasal, topical, transdermal, and an implant under the skin.

Continuity (4)
Continuation 16827194 · Mar 23, 2020
Continuation 15987420 · May 23, 2018
Provisional Application 62510554 · May 24, 2017
Related Publication 20230355585A1 · Nov 9, 2023
References Cited (85)
US 5171750A · Brossi et al. · 1992 [cited by applicant]
US 5409948A · Greig et al. · 1995 [cited by applicant]
US 6410747B1 · Greig et al. · 2002 [cited by applicant]
US 6495700B1 · Bruening et al. · 2002 [cited by applicant]
US 6683105B2 · Greig et al. · 2004 [cited by applicant]
US 7153882B2 · Grieg et al. · 2006 [cited by applicant]
US 7625942B2 · Bruinsma et al. · 2009 [cited by applicant]
US 7786162B2 · Grieg et al. · 2010 [cited by applicant]
US 7994210B2 · Bruinsma et al. · 2011 [cited by applicant]
US 8258172B2 · Greig et al. · 2012 [cited by applicant]
US 8691864B2 · Greig et al. · 2014 [cited by applicant]
US 11596621B2 · Maccecchini · 2023 [cited by examiner]
US 20020094999A1 · Grieg et al. · 2002 [cited by applicant]
US 20040024043A1 · Greig et al. · 2004 [cited by applicant]
US 20050013869A1 · Chaw et al. · 2005 [cited by applicant]
US 20050182044A1 · Bruinsma · 2005 [cited by applicant]
US 20050272804A1 · Bruinsma · 2005 [cited by applicant]
US 20070037848A1 · Masters et al. · 2007 [cited by applicant]
US 20100298389A1 · Elmaleh et al. · 2010 [cited by applicant]
US 20110021594A1 · Grieg et al. · 2011 [cited by applicant]
US 20120225922A1 · Maccecchini · 2012 [cited by applicant]
WO WO0166114 · 2001 [cited by applicant]
WO WO0248150 · 2002 [cited by applicant]
WO WO03082270 · 2003 [cited by applicant]
WO WO2004034963 · 2004 [cited by applicant]
WO WO2005089746 · 2005 [cited by applicant]
WO WO2005123068 · 2005 [cited by applicant]
WO WO2010117727 · 2010 [cited by applicant]
WO WO2012154285 · 2012 [cited by applicant]
WO WO2014179303A1 · 2014 [cited by applicant]
WO WO2017030968 · 2017 [cited by applicant]
Cullen et al. “Brain Beta-Amyloid 42 in Mice Treated Orally with Posiphen Tartrate is Significantly Lower than in Vehicle Controls,” 9 [cited by applicant]
Holloway et al. “Mechanism of Action of Posiphen in CSF of mildly Cognitive Impaired Patients,” QR Pharma, Inc., Radnor, PA. [cited by applicant]
Soares et al., “Aβ Variability and Effects of Gamma Secretase Inhibition on Plasma and Cerebrospinal Fluid Levels of Aβ Peptide in Healthy Volunteers” Pfizer Global Research and Development, New London, CT. [cited by applicant]
Marutle et al. “Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine” The National Academy of Sciences of the USA; vol. 104, No. 30, pp. 12506-12511, (Jul. 24, 2007). [cited by applicant]
Brazzolotto et al., “Structural Changes Associated with Switching Activities of Human Iron Regulatory Protein 1*” The Journal of Biological Chemistry; vol. 277, No. 14, pp. 11995-12000, (2002). [cited by applicant]
Shaw et al., “Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development” PNAS, vol. 98, No. 13; pp; 7605-7610, (Jun. 19, 2001). [cited by applicant]
Lahiri et al. “The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice” The Journal of Pharmacology and Experimental Therapeutics, vol. 320, No. 1; pp… [cited by applicant]
Selkoe, “Defining Molecular Targets to Prevent Alzheimer Disease” American Medical Association; pp. 192-195; (2005). [cited by applicant]
Kadir et al. “Effect of Phenserine Treatment on Brain Functional Activity and Amyloid in Alzheimer's Disease” American Neurological Association, Wiley-Liss, Inc.; pp. 621-631; (2008). [cited by applicant]
Khachaturian, “Diagnosis of Alzheimer's Disease” Arch Neurology; vol. 42, pp. 1097; (Nov. 1985). [cited by applicant]
Cahill et al. “Amyloid Precursor Protein and Alpha Synuclein Translation, Implications for Iron and Inflammation in Neurodegenerative diseases” [cited by applicant]
Maccecchini et al. “ Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and levels: target engagement, tolerability and pharmacokinetics in humans” J Neurol Neurosurg Psychiatry; vol.… [cited by applicant]
Duce et al. “Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease” Cell; pp. 1-10; (2010), doi: 10.1016/j.cell.2010.08.014. [cited by applicant]
Kounnas et al. “Modulation of -Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease” Neuron; pp. 1-12; (2010). [cited by applicant]
Mikkilineni et al. “The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5' Untranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression” Hindawi Publishing Corporation; vo… [cited by applicant]
Venti et al. “The Integrated Role of Desferrioxamine and Phenserine Targeted to an Iron-Responsive Element in the APP-mRNA 5'-Untranslated Region” Ann. N.Y. Acad. Sci. Vol 1035: pp. 34-58 (2004). [cited by applicant]
Bandyopadhyay et al. “Novel 5' Untranslated Region Directed Blockers of Iron-Regulatory Protein-1 Dependent Amyloid Precursor Protein Translation: Implications for Down Syndrome and Alzheimer's Disease” PLOS One; vol. 8… [cited by applicant]
Maccecchini, “Targeting Alzheimer's with Novel Therapeutics” QR Pharma, Inc. Neuroscience Network; presented by Maria Maccecchini on May 11, 2010. [cited by applicant]
Harold W Holloway et al: “Posiphen and Analogs: Experimental Alzheimer' Agents that Reduce Amyloid-[beta] Peptide by Lowering Amyloid Precursor Protein Levels in Culture and In Vivo” , 42nd Annual Winter Conference on B… [cited by applicant]
Maccecchini et al: “Targeting Alzheimer's with Novel Therapeutics”, May 11, 2010 (May 11, 2010), Neuroscience Network, << http:l/www.qrpharma.comlpdf/2010-5-11 Alzheimers Research Today Maria Maccecchini slides.pdf>>. L… [cited by applicant]
Maria L. Maccecchini: “Mechanism of Action of Posiphen : From Model to Human” , Jan. 26, 2011 (Jan. 26, 2011) , 44nd Annual Winter Conference on Brain Research, << http://wwwqrpharma.com/pdfIWCBR Talk Jan 2011.pdf>>. La… [cited by applicant]
Kadir et al: “Long-term effect of phenserine treatment in Alzheimer patients as assessed by PET and CSF biomarkers”, Alzheimer's & Dementia the Journal of the Alzheimer's Association vol. 5, No. 4; p. 6. [cited by applicant]
Melo et al. Annals of the NY Academy of Sci., 1096, 1, 2007. [cited by applicant]
Maccecchini et al. (Poster presentations, Alzheimer's and Dementia, Jul. 2009, 5, 4, S1, p. 247-248). [cited by applicant]
Lahiri et al. (The J of Pharmacology and Experimental Therapeutics, 320, 1, 386-396, 2007). [cited by applicant]
Tomiyama, (The J of Biol. Chem, 271, 12, 6839-44, 1996). [cited by applicant]
Galvan, et al., “Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664,” PNAS, May 2, 2006, I03(18): pp. 7130-7135. [cited by applicant]
Nikolaev, et al., “APP binds DR6 to trigger axon pruning and neuron death via distinct caspases,” Nature, Feb. 19, 2009, 457(19): pp. 981-990. [cited by applicant]
Takeda, et al., “Mechanisms ofNeuronal Death in Synucleinopathy,” Journal ofBiomedicine and Biotechnology, 2006, vol. 2006, Article ID 19365, pp. 1-4. [cited by applicant]
Rogers, et al., “The alpha-synuclein 5 'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen,” .1. Neural Transm, Oct. 15, 2010, DOI 10.1007/s00702-010-0513… [cited by applicant]
Cho, et al., “Selective Translational Control of the Alzheimer Amyloid Precursor Protein Transcript by Iron Regulatory Protein-1,” Journal ofBiological Chemistry, Oct. 8, 2010, 285(41): pp. 31217-31232. [cited by applicant]
Khachaturian, “Diagnosis of Alzheimer's Disease,” Arch Neural, Nov. 1985, 42: pp. 1097-1105. [cited by applicant]
International Search Report from International WIPO Publication No. WO 2012/154285 dated Aug. 17, 2012. [cited by applicant]
Maccecchini et al. “Posiphen lowers amyloid precursor protein and amyloid beta as well as acetylcholinesterase levels in culture, animals and humans” International Conference on Alzheimer's Disease; Jul. 12, 2009 (Abstr… [cited by applicant]
Greig et al. “The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics” Acta Neurol Scand 2000: Supplement 176: pp. 74-84. [cited by applicant]
Office Action from corresponding Korean Patent Application No. 10-2013-7025992 dated Jul. 30, 2018. [cited by applicant]
Janas et al. “The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats” Life Sciences, Pergamon Press, Oxford, GB, vol. 76, No. 10, (Jan. 21, 2005) pp. 1073-1081. [cited by applicant]
Pike et al. “Effect of tetrahydroaminoacridine, a cholinesterase inhibitor, on cognitive performance following experimental brain injury” Journal of Neurotrauma, vol. 14, No. 12, (Dec. 1997) pp. 897-905. [cited by applicant]
David et al. “Cognitive impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms” POLS One, vol. 11, No.… [cited by applicant]
International Search Report from International PCT Application No. PCT/US2016/046794 dated Feb. 23, 2017. [cited by applicant]
Hentze et al., “Two to Tango: Regulation of Mammalian Iron Metabolism” Cell. Jul. 9, 2010, vol. 142, No. 1, pp. 42-38; abstract; p. 26, 2 [cited by applicant]
International Search Report from International PCT Application No. PCT/US18/34130 dated Sep. 4, 2018. [cited by applicant]
International Written Opinion from International PCT Application No. PCT/US2018/034130 dated Nov. 26, 2019. [cited by applicant]
U.S Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) “Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for The… [cited by applicant]
Maccecchini et al. “Posiphen: Experimental Alzheimer Agent that Lowers Amyloid Precursor Protein Levels in Culture and In Vivo”; Dept. Psychiatry, Institute Psychiatric Research, Indiana Univ., Indianapolis, IN: Departm… [cited by applicant]
Summons to Attend Oral Proceedings mailed on Apr. 25, 2019 in connection to European Patent Application No. 12 782 326.8. [cited by applicant]
Larson et al. (Annu. Rev. Publ. Health 13L431-49) (Year: 1992). [cited by applicant]
CAS Registry (1998, p. 1) (Year: 1998). [cited by applicant]
Phukan et al. (http://neurology.thelancet.com, vol. 6, Nov. 2007). (Year: 2007). [cited by applicant]
Klein (Phenserine, Expert Opin Investig. Drugs 2007, 16(7): 1087-1097 (Year: 2007). [cited by applicant]
Enright (https://louisaenright.com/2011 /11 /), 2011 (Year: 2011). [cited by applicant]
Novak et al. (Huntington's Disease, BMJ, Jul. 3, 2010). (Year: 2010). [cited by applicant]
European Search Report from corresponding application EP 18 80 5102 dated May 12, 2021. [cited by applicant]
Bush J. of Alzheimer's Dis, 2013, 33 Suppl 1: S277-81. [cited by applicant]